Archives
-
ATM Inhibition Induces Macropinocytosis and Reveals Metaboli
2026-05-30
Huang et al. uncover that ATM kinase inhibition triggers metabolic adaptation in cancer cells by inducing macropinocytosis, enabling survival under nutrient-poor conditions. This work highlights a novel tumor suppressor function of ATM and identifies a potential metabolic vulnerability exploitable in cancer therapy research.
-
Frizzled5: Linking Cholesterol Metabolism to Wnt Signaling i
2026-05-29
This study uncovers a unique mechanism by which Frizzled5 (Fzd5) directly binds cholesterol, enabling its maturation and activating Wnt/β-catenin signaling in pancreatic ductal adenocarcinoma (PDAC). These findings establish a molecular connection between aberrant cholesterol metabolism and oncogenic signaling, suggesting new therapeutic strategies for Wnt-driven cancers.
-
Perphenazine: Dopamine D2 Antagonist in Advanced Bench Resea
2026-05-29
Perphenazine delivers unique multi-receptor antagonism, enabling precise modulation of dopaminergic and immune pathways in both neuropharmacology and host-pathogen studies. Its robust, quantifiable effects on cell death and innate immunity make it a high-value tool for researchers tackling complex disease models and seeking alternatives to conventional antibiotics.
-
Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in
2026-05-28
Xie et al. introduce a dual recombinase-mediated genetic tracing approach to rigorously test whether adult female mice can regenerate oocytes after birth. Their findings provide strong evidence that postnatal neo-oogenesis does not occur in vivo, even after germ cell depletion, refining our understanding of ovarian biology and experimental modeling.
-
ATRX Loss Sensitizes Glioma Cells to Selective PDGFR Inhibit
2026-05-28
Recent evidence demonstrates that ATRX-deficient high-grade glioma cells are notably more sensitive to receptor tyrosine kinase and PDGFR inhibitors. This finding highlights a potential biomarker-driven therapeutic strategy and underscores the relevance of ATRX mutation status in designing targeted interventions for aggressive gliomas.
-
Advancing Capture-and-Release Assays with TCEP Hydrochloride
2026-05-27
Explore how Tris(2-carboxyethyl) phosphine hydrochloride (TCEP hydrochloride) transforms cleavable linker workflows and protein analysis in translational research, with mechanistic depth, protocol recommendations, and strategic guidance for next-generation assay design.
-
Verapamil HCl Regulates Txnip to Counter Osteoporosis: New I
2026-05-27
This study uncovers how the clinically used L-type calcium channel blocker Verapamil HCl rescues bone loss in postmenopausal osteoporosis models by suppressing Txnip expression and modulating both osteoclast and osteoblast pathways. The findings provide a mechanistic bridge between calcium signaling modulation and bone turnover, opening new perspectives for translational osteoporosis research.
-
Nelfinavir Mesylate: Precision HIV-1 Protease Inhibitor in R
2026-05-26
Nelfinavir Mesylate delivers dual impact as a benchmark HIV-1 protease inhibitor and a powerful modulator of ferroptosis via the ubiquitin-proteasome system, making it indispensable for both antiviral and cell death pathway research. This article bridges advanced experimental workflows, troubleshooting strategies, and the latest mechanistic insights to help researchers unlock new frontiers in HIV suppression and regulated cell death modeling.
-
Phenylmethanesulfonyl Fluoride (PMSF) in Protein Extraction
2026-05-26
Phenylmethanesulfonyl fluoride (PMSF) is the gold-standard irreversible serine protease inhibitor, essential for preserving protein integrity in demanding workflows like Western blotting and epigenetic analysis. This guide translates recent research and practical expertise into actionable protocols, troubleshooting insights, and advanced strategies, empowering researchers to maximize data reliability with APExBIO’s PMSF.
-
Olsalazine Sodium: Applied Workflows in Cancer and Inflammat
2026-05-25
Olsalazine Sodium, a potent mesalamine dimer, accelerates anti-inflammatory and tumor apoptosis research thanks to its unique solubility and validated biological activity. Learn how recent experimental insights and protocol optimization strategies can transform colorectal cancer and vector biology investigations.
-
Guanabenz Acetate: Precision α2-Adrenergic Receptor Agonist
2026-05-25
Guanabenz Acetate enables reproducible modulation of α2-adrenergic receptor pathways, empowering researchers to dissect GPCR signaling and stress response mechanisms with subtype-selective precision. Learn how to maximize assay reliability, troubleshoot solubility and stability, and leverage recent advances in immune pathway interrogation.
-
Z-VDVAD-FMK: Precision Caspase-2 Inhibition in Apoptosis Ass
2026-05-24
Z-VDVAD-FMK empowers apoptosis research by providing robust, selective caspase-2 inhibition and clear mechanistic dissection of mitochondrial cell death pathways. Its reliable solubility, cross-caspase coverage, and protocol flexibility set it apart for translational and cancer research applications.
-
Aclacinomycin A Workflows: Precision DNA Damage & Apoptosis
2026-05-23
Aclacinomycin A (Aclarubicin) empowers researchers with dual topoisomerase inhibition for high-fidelity modeling of DNA damage and apoptosis. By leveraging validated protocols and troubleshooting strategies, labs can achieve reproducible, mechanistically insightful results in cancer cell systems.
-
Mechanisms of Spiroplasma eriocheiris Entry via Endocytosis
2026-05-22
Wei et al. reveal that Spiroplasma eriocheiris invades Drosophila Schneider 2 cells primarily through clathrin-mediated endocytosis and macropinocytosis, not caveolae-dependent pathways. Their experimental model clarifies host-pathogen interactions and provides a robust framework for dissecting endocytic mechanisms in invertebrate infection biology.
-
L1023 Anti-Cancer Compound Library: Optimizing High-Throughp
2026-05-22
The L1023 Anti-Cancer Compound Library empowers cancer researchers to rapidly interrogate oncogenic signaling and accelerate biomarker-driven drug discovery. With pre-dissolved, pathway-specific agents and robust validation, L1023 streamlines high-throughput screening and maximizes reproducibility for even the most challenging oncology targets.